Clinical trials: Movement Abnormalities
Dyskinesia, Levodopa Induced Dyskinesia
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 4-arm parallel group study to evaluate the tolerability and efficacy of each of three dose levels of ADS-5102 oral capsules, an extended release formulation of…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
- Trial name
- EASED (NCT01397422)
- Testing
- ADS-5102 (extended release amantadine HCl)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson's Disease, Healthy
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's…
- Trial name
- NCT02459886
- Testing
- BIIB054
- Where
- 9 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Biogen
Parkinson Disease
Prospective Study for Neuromelanin Image Analysis
In order to develop an image analysis system that automatically detects and quantifies neuromelanin, this study aims to construct a database of a wide sample by collecting brain MRI neuromelanin images prospectively.
- Trial name
- NCT05513794
- Testing
- MRI Imaging
- Where
- 3 sites in South Korea
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Heuron Inc.
Huntington Disease
Riluzole in Huntington's Disease
Primary objective: The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating…
- Trial name
- NCT00277602
- Testing
- Riluzole
- Volunteers
- 537 people
- Sponsor
- Sanofi
Parkinson Disease
Adaptive Deep Brain Stimulation (aDBS) Study (Early Adapter) Part II
The purpose of the study is to evaluate the efficacy of aDBS (preferred mode, single or dual threshold) vs standard continuous DBS (cDBS) in decreasing Total Electrical Energy Delivered (TEED).
- Trial name
- NCT07106242
- Testing
- Adaptive DBS, cDBS
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- MedtronicNeuro
Wilson Disease
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.
- Trial name
- NCT02426905
- Testing
- trientine dihydrochloride
- Where
- 4 sites in Germany, Greece and 2 more
- Volunteers
- 90 people
- Sponsor
- Univar BV
Parkinson's Disease, Idiopathic
Study for the Early Diagnosis of Parkinson's Disease
The main objective of the study is to design and validate the blood based PDx gene expression and miRNA assay for the early diagnosis of Parkinson's disease patients.
- Trial name
- NCT02283073
- Where
- 6 sites in Israel, Italy
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Bio Shai Ltd.
Parkinson's Disease
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.
- Trial name
- NCT00199394
- Testing
- Istradefylline (KW-6002)
- Where
- United Kingdom
- Volunteers
- 405 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study
An extension of study IN 09 004 testing the long term safety of the Accordion Pill Carbidopa/Levodopa (AP-CD/LD)
- Trial name
- NCT00947037
- Testing
- AP-CD/LD
- Where
- 5 sites in Israel
- Sponsor
- Intec Pharma Ltd.
Parkinson's Disease
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study
The objective of this study is to evaluate the effectiveness of Deep Brain Stimulation as an adjunctive treatment for reducing some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately…
- Trial name
- NCT01352819
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 21 people
- Sponsor
- Abbott Medical Devices
Parkinson's Disease
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation [administered with Lodosyn® (carbidopa)] and Sinemet® tablets in subjects with Parkinson's disease…
- Trial name
- NCT00914602
- Testing
- Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- XenoPort, Inc.
Parkinson's Disease
Azilect® In Wearing-Off (AIWO)
End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication.
- Trial name
- AIWO (NCT02384512)
- Testing
- Azilect®
- Where
- 140 sites in Germany
- Volunteers
- 261 people
- Sponsor
- Teva Pharma GmbH
Multiple System Atrophy (MSA)
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA.
- Trial name
- NCT05923866
- Testing
- ONO-2808
- Where
- 35 sites in United States, Japan
- Volunteers
- 92 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Parkinson Disease
Expanded Access to Tavapadon
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to tavapadon prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT07158827
- Testing
- Tavapadon
- Sponsor
- AbbVie
Tic Disorder, Tourette Syndrome
Phase III Study of 5LGr to Treat Tic Disorder
The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric patients with tic disorders.
- Conditions
- Tic Disorder, Tourette Syndrome, Chronic Tic Disorder
- Trial name
- 5LGr (NCT01501695)
- Testing
- 5LGr, tiapride
- Volunteers
- 603 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Parkinson Disease
Utilization of Target Ranges to Treat Parkinson's Disease With the PKG
The main objective of this study is to evaluate whether people whose PD symptoms are uncontrolled who are managed with the aid of objective measurement and use of target ranges have improved PD symptoms and outcomes as compared…
- Trial name
- TARGET-PD (NCT03984305)
- Testing
- Personal KinetiGraph® (PKG®) Watch, Personal KinetiGraph® (PKG®) Report
- Where
- 17 sites in United States
- Volunteers
- 41 people
- Sponsor
- Global Kinetics Corporation
Parkinson Disease (PD)
Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).
- Trial name
- NCT02485600
- Where
- 13 sites in Canada
- Volunteers
- 88 people
- Sponsor
- AbbVie
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Parkinson Disease
Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease
Study to obtain information about the co-operation of the different physician-colleagues in the treatment of patients with Parkinson's disease, both in private practices and clinics and about the primary treatment strategies in…
- Trial name
- NCT02248207
- Testing
- Pramipexole
- Volunteers
- 1,293 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.